A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 - Claudin18.2 Monoclonal Antibody in the Treatment of Locally Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osemitamab (Primary) ; Capecitabine; Nivolumab; Oxaliplatin
Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Ductal carcinoma; Gallbladder cancer; Gastric cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms TranStar102
Sponsors MabSpace Biosciences

Most Recent Events

21 Oct 2024 Planned End Date changed from 1 Nov 2024 to 1 May 2025.
21 Oct 2024 Planned primary completion date changed from 31 Aug 2024 to 25 Feb 2025.
19 Sep 2024 Updated results presented in a Transcenta Holding Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight